Capital Fund Management S.A. Makes New $5.61 Million Investment in Halozyme Therapeutics, Inc. $HALO

Capital Fund Management S.A. purchased a new stake in Halozyme Therapeutics, Inc. (NASDAQ:HALO) during the second quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The fund purchased 107,911 shares of the biopharmaceutical company’s stock, valued at approximately $5,614,000. Capital Fund Management S.A. owned approximately 0.09% of Halozyme Therapeutics at the end of the most recent reporting period.

A number of other hedge funds have also modified their holdings of HALO. DLD Asset Management LP bought a new stake in Halozyme Therapeutics in the 2nd quarter valued at approximately $650,250,000. Alliancebernstein L.P. raised its holdings in shares of Halozyme Therapeutics by 4.8% in the first quarter. Alliancebernstein L.P. now owns 3,215,109 shares of the biopharmaceutical company’s stock valued at $205,156,000 after purchasing an additional 146,677 shares during the last quarter. Dimensional Fund Advisors LP lifted its position in shares of Halozyme Therapeutics by 4.9% in the first quarter. Dimensional Fund Advisors LP now owns 2,029,160 shares of the biopharmaceutical company’s stock worth $129,478,000 after purchasing an additional 95,600 shares in the last quarter. LSV Asset Management boosted its holdings in Halozyme Therapeutics by 40.2% during the second quarter. LSV Asset Management now owns 1,255,240 shares of the biopharmaceutical company’s stock worth $65,298,000 after purchasing an additional 360,049 shares during the last quarter. Finally, Fuller & Thaler Asset Management Inc. grew its position in Halozyme Therapeutics by 27.3% in the first quarter. Fuller & Thaler Asset Management Inc. now owns 1,130,019 shares of the biopharmaceutical company’s stock valued at $72,107,000 after purchasing an additional 242,167 shares in the last quarter. 97.79% of the stock is currently owned by institutional investors.

Wall Street Analysts Forecast Growth

Several equities research analysts have commented on the stock. HC Wainwright reissued a “buy” rating and set a $90.00 price target on shares of Halozyme Therapeutics in a research report on Friday. Weiss Ratings reissued a “buy (b)” rating on shares of Halozyme Therapeutics in a research report on Wednesday, November 19th. Citizens Jmp raised their price target on Halozyme Therapeutics from $91.00 to $92.00 and gave the company a “market outperform” rating in a research note on Tuesday, November 4th. Morgan Stanley dropped their price objective on Halozyme Therapeutics from $80.00 to $79.00 and set an “overweight” rating on the stock in a research note on Monday, October 20th. Finally, Benchmark raised their target price on shares of Halozyme Therapeutics from $75.00 to $90.00 and gave the company a “buy” rating in a research note on Wednesday, September 24th. Seven research analysts have rated the stock with a Buy rating and seven have given a Hold rating to the company. According to data from MarketBeat, Halozyme Therapeutics currently has an average rating of “Moderate Buy” and a consensus price target of $75.10.

Halozyme Therapeutics Stock Performance

HALO opened at $71.39 on Monday. The company has a quick ratio of 7.01, a current ratio of 8.36 and a debt-to-equity ratio of 4.54. Halozyme Therapeutics, Inc. has a 12-month low of $46.26 and a 12-month high of $79.50. The business has a 50 day moving average of $69.25 and a 200-day moving average of $63.96. The stock has a market cap of $8.39 billion, a price-to-earnings ratio of 16.34, a PEG ratio of 0.35 and a beta of 1.18.

Halozyme Therapeutics (NASDAQ:HALO) last posted its quarterly earnings results on Monday, November 3rd. The biopharmaceutical company reported $1.72 earnings per share for the quarter, beating analysts’ consensus estimates of $1.63 by $0.09. Halozyme Therapeutics had a return on equity of 150.85% and a net margin of 47.28%.The business had revenue of $354.26 million for the quarter, compared to analysts’ expectations of $339.18 million. During the same quarter in the prior year, the business earned $1.27 EPS. The firm’s revenue for the quarter was up 22.1% on a year-over-year basis. On average, equities research analysts expect that Halozyme Therapeutics, Inc. will post 4.73 earnings per share for the current year.

Insider Activity

In other Halozyme Therapeutics news, CEO Helen Torley sold 20,000 shares of the firm’s stock in a transaction that occurred on Tuesday, November 11th. The shares were sold at an average price of $69.13, for a total transaction of $1,382,600.00. Following the completion of the sale, the chief executive officer directly owned 733,719 shares in the company, valued at $50,721,994.47. This trade represents a 2.65% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available at this hyperlink. Also, Director Bernadette Connaughton sold 4,000 shares of the business’s stock in a transaction that occurred on Tuesday, September 2nd. The stock was sold at an average price of $73.68, for a total value of $294,720.00. Following the sale, the director owned 46,952 shares of the company’s stock, valued at approximately $3,459,423.36. This represents a 7.85% decrease in their position. The disclosure for this sale is available in the SEC filing. Insiders have sold 110,227 shares of company stock valued at $8,028,955 over the last ninety days. 2.40% of the stock is currently owned by company insiders.

About Halozyme Therapeutics

Halozyme Therapeutics, Inc, a biopharma technology platform company, researches, develops, and commercializes proprietary enzymes and devices in the United States, Switzerland, Belgium, Japan, and internationally. The company's products are based on the patented recombinant human hyaluronidase enzyme (rHuPH20) that enables delivery of injectable biologics, such as monoclonal antibodies and other therapeutic molecules, as well as small molecules and fluids.